Effect of Melatonin Administration on Systemic Lupus Erythematosus Patients (SLE)
Effect of Melatonin Administration on the Clinical Outcomes of Systemic Lupus Erythematosus Patients
研究概览
详细说明
Systemic lupus erythematosus (SLE) is a multisystem chronic autoimmune disease with a relapsing and remitting course. Its prevalence is higher in women of childbearing age of non-white ethnicity. It has a broad spectrum of clinical features ranging from mild cutaneous involvement to severe organ damage, such as kidney failure, pulmonary hypertension, and cardiac failure. The exact etiology of the disease is not well understood well. However, inflammation and oxidative stress are among the most important targets for the management of SLE. Elevated circulating IL-6 concentrations have been consistently observed in patients with systemic lupus erythematosus (SLE) relative to healthy controls, underscoring its pathogenic relevance. In systemic lupus erythematosus (SLE), excessive oxidative stress arising from chronic inflammation and immune complex deposition leads to depletion of endogenous antioxidants, including SOD.
Moreover, diminished SOD activity correlates with disease activity indices such as SLEDAI, suggesting its potential utility as a biomarker for oxidative stress-related disease burden.
melatonin has anti-inflammatory and anti-oxidant characteristics that may aid in the management of autoimmune diseases. In different animal models, melatonin has demonstrated to ameliorate lupus nephritis, reduce inflammation, and improve overall disease pathology. However, these studies have their limitations of being performed in vitro.Only one randomized controlled trial (RCT) was conducted on adult SLE patients and showed improvement in oxidative stress markers, namely malondialdehyde and total antioxidant capacity but no effect on disease activity.
The aim of the current study is to evaluate the effect of melatonin administration on circulating levels of inflammatory mediators, oxidative stress, sleep quality, fatigue and quality of life in patients with SLE. To the best of our knowledge, this is the first randomized-controlled trial to evaluate the impact of melatonin on sleep quality and assess fatigue and quality of life in SLE adult patients. Moreover, the impact of melatonin on serum concentrations of Interleukin-6 and superoxide dismutase SOD will be evaluated.
研究类型
注册 (估计的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习联系方式
- 姓名：Nirmeen A. Habib, Master
- 电话号码：+201124147642
- 邮箱：nirmeen.ms2324020@pharma.asu.edu.eg
研究联系人备份
- 姓名：Areej M. Ateya, lecturer
- 电话号码：+201003152806
- 邮箱：areeg.mohamed@pharma.asu.edu.eg
学习地点
-
-
-
Cairo、埃及
- Department of Rheumatology Ain Shams University hospitals
-
接触：
- Nirmeen Amr Habib Nirmeen Amr
- 电话号码：+201124147642
- 邮箱：nirmeen.ms2324020@pharma.asu.edu.eg
-
接触：
- Areej Mohamed Atya Lecturer, PhD
- 电话号码：+201003152806
- 邮箱：areeg.mohamed@pharma.asu.edu.eg
-
-
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- Adult male and female patients with active SLE aged 18-60 years
- Active SLE patients defined on SLEDAI-2K score to be (more than or equal 4 up to 11) according to the classification of SLE as suggested by the American Rheumatology Association (American College of Rheumatology)
- Have had non-life-threatening disease
- Taking stable doses of medications for SLE treatment in the last three months
- Ability and willingness to cooperate in the study
Exclusion Criteria:
- Other autoimmune diseases
- Uncontrolled hypertension or Uncontrolled DM
- Severe renal (GFR < 30 ml/min ) or severe liver diseases (ALT or AST <3 times ULN or total bilirubin > 2 times ULN)
Life-threatening SLE including
- Severe hemolysis (reticulocyte count >8%)
- Severe thrombocytopenia (platelet count <40 000)
- Endocarditis
- Lupus pneumonia
- Alveolar hemorrhage
- Using sedations, antidepressants, contraceptives, antioxidant and/or omega-3-fatty acid supplements one month prior to or during the study
- Smoking and/ or alcohol intake
- Allergy to melatonin
- Pregnancy, pregnancy plans and lactation.
- Having active infectious diseases
- poor patient compliance
- Any sleeping pills two weeks prior to the study
- Malabsorption syndromes
- Malignancy
- Warfarin or heparin use or high-dose aspirin (more than 325 mg/day)
- Stroke
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Melatonin group
32 patients will receive the standard of care treatment in addition to melatonin oral drug (15 mg/day) once daily for 12 weeks taken 30 minutes to 1 hour before bedtime.
|
32 patients will receive the standard of care treatment in addition to melatonin oral drug (15 mg/day) once daily for 12 weeks taken 30 minutes to 1 hour before bedtime.
|
|
无干预：Control group:
32 patients will receive standard of care
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Serum Interleukin- 6 (IL-6)
大体时间：at baseline and then after 12 weeks
|
Blood samples will be drawn from the patients at baseline and after 12 weeks of intervention.
Blood samples will be collected at baseline, centrifuged and stored as serum at - 80°C or -20°C until analysis.
Enzyme-linked immunosorbent assay (ELISA) method will be used to measure Interleukin 6 concentrations
|
at baseline and then after 12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
SLEDAI -2K Score
大体时间：at baseline and then after 12 weeks
|
A)Items: It includes 24 items, with 16 clinical and 8 laboratory-based descriptors. B)Domains: The items are grouped into nine organ systems: central nervous system, vascular, musculoskeletal, serosal, dermal, constitutional, renal, immunological, and hematological. C)Scoring: Each item is scored as present or absent, typically based on the preceding 30 days. D)Total Score: The individual item scores are summed to produce a global score, ranging from 0 to 105. |
at baseline and then after 12 weeks
|
|
Serum SOD
大体时间：at baseline and after 12 weeks
|
Superoxide dismutase (SOD) measured by Spectrophotometric Method, by tracking the inhibition of superoxide radical-driven reactions, often involving the reduction of nitro blue tetrazolium (NBT) or the autoxidation of other compounds like BXT-01050, which produce a color change that is measured at a specific wavelength, typically around 525 nm or 560-562 nm.
The rate of this color change in the presence of a sample is compared to the rate in a blank, with the percent inhibition of the reaction directly correlating to the amount of SOD present in the sample.
|
at baseline and after 12 weeks
|
|
Arabic version form of Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL-Arabic Version)
大体时间：at baseline -1st Month-2nd Month-3rd Month
|
The questionnaire consists of 40 items covering multiple domains relevant to SLE. These items are grouped into 6 domains which are:
|
at baseline -1st Month-2nd Month-3rd Month
|
|
Arabic version of Fatigue Severity Scale (FSS)
大体时间：at baseline -1st Month-2nd Month-3rd Month
|
FSS is a self-reported questionnaire that is simple and easy to use.
It consists of 9 statements that rate the severity of the patient's fatigue symptoms in terms of how these symptoms affect motivation, exercise, physical function, and activities of daily living Reflecting on their condition over the past month, patients score each item from 1 to 7, based on the extent, to which they agree or disagree with each statement (1 = strong disagreement, 7 = strong agreement).
|
at baseline -1st Month-2nd Month-3rd Month
|
|
Arabic Version of the Pittsburgh Sleep Quality Index (PSQI)
大体时间：at baseline- 1st Month-2nd Month-3rd Month
|
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.
Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.
The sum of scores for these seven components yields one global score.
Each weighed equally on a O-3 scale.
The seven component scores are then summed to yield a global PSQI score, which has a range of O-2 I; higher scores indicate worse sleep quality.
|
at baseline- 1st Month-2nd Month-3rd Month
|
|
Incidence of Adverse Effects and Medication Adherence & Modifications
大体时间：weekly up to 12 weeks
|
All patients in both arms will be followed weekly by a telephone call for reporting of any adverse effects from melatonin and patients will be given a side effect-reporting card and will be educated on how to use it.
Moreover, compliance to medications and any change of doses or addition or discontinuation of medications will be assessed.
|
weekly up to 12 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- RHDIRB2020110301 REC # 444
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.